


**AMENDMENTS TO THE CLAIMS:**

Amend the claims as follows:

Claims 1-79. (Canceled).

80. (Currently Amended) A compound of the formula:



wherein:

~~Cy is independently a cyclyl group;~~

~~Q<sup>1</sup> is independently a covalent bond or cyclyl leader group;~~

the piperazin-1,4-diyl group is optionally substituted;

J<sup>1</sup> is independently a covalent bond or -C(=O)- ;

J<sup>2</sup> is independently -C(=O)- or -S(=O)<sub>2</sub>- ;

~~Q<sup>2</sup> is independently an acid leader group;~~

wherein:

Cy is independently:

C<sub>3-20</sub>carbocyclyl,

C<sub>3-20</sub>heterocyclyl, or

C<sub>5-20</sub>aryl;

and is optionally substituted;

Q<sup>1</sup> is independently:

a covalent bond;

C<sub>1-7</sub>alkylene; or

C<sub>1-7</sub>alkylene-X-C<sub>1-7</sub>alkylene, -X-C<sub>1-7</sub>alkylene, or C<sub>1-7</sub>alkylene-X-,

wherein X is -O- or -S-;

and is optionally substituted;

Q<sup>2</sup> is independently:

C<sub>4-8</sub>alkylene;

and is optionally substituted;

and has a backbone length of at least 4 atoms;

or:

Q<sup>2</sup> is independently:

—C<sub>5-20</sub>arylene;

C<sub>5-20</sub>arylene-C<sub>1-7</sub>alkylene;

C<sub>1-7</sub>alkylene-C<sub>5-20</sub>arylene; or,

C<sub>1-7</sub>alkylene-C<sub>5-20</sub>arylene-C<sub>1-7</sub>alkylene;

and is optionally substituted;

and has a backbone length of at least 4 atoms;

or a pharmaceutically acceptable salt, solvate, amide, ester, or ether, ~~chemically protected form, or prodrug~~ thereof.

81. (Currently Amended) A compound according to claim 80, wherein the piperazin-1,4-diyl group is unsubstituted or substituted at one or more of the 2-, 3-, 5-, and 6-positions with C<sub>1-4</sub>alkyl.

82. (Previously Presented) A compound according to claim 80, wherein: J<sup>1</sup> is a covalent bond; and J<sup>2</sup> is -C(=O)-.

83. (Previously Presented) A compound according to claim 80, wherein: J<sup>1</sup> is -C(=O)-; and J<sup>2</sup> is -C(=O)-.

84. (Previously Presented) A compound according to claim 80, wherein: J<sup>1</sup> is a covalent bond; and J<sup>2</sup> is -S(=O)<sub>2</sub>-.

Claim 85. (Canceled)

Claim 86. (Canceled)

87. (Previously Presented) A compound according to claim 80, wherein  $Q^1$  is independently  $C_{1-7}$ alkylene, and is optionally substituted.

88. (Previously Presented) A compound according to claim 80, wherein:  $Q^1$  is independently  $C_{1-7}$ alkylene, and is optionally substituted;  $J^1$  is independently a covalent bond;  $J^2$  is independently  $-C(=O)-$ .

89. (Previously Presented) A compound according to claim 80, wherein:  $Q^1$  is independently  $C_{1-7}$ alkylene, and is optionally substituted;  $J^1$  is independently  $-C(=O)-$ ;  $J^2$  is independently  $-C(=O)-$ .

90. (Previously Presented) A compound according to claim 80, wherein:  $Q^1$  is independently  $C_{1-7}$ alkylene, and is optionally substituted;  $J^1$  is independently a covalent bond;  $J^2$  is independently  $-S(=O)_2-$ .

91. (Previously Presented) A compound according to claim 80, wherein:  $Q^1$  is independently  $C_{1-7}$ alkylene, and is optionally substituted;  $J^1$  is independently  $-C(=O)-$ ;  $J^2$  is independently  $-S(=O)_2-$ .

92. (Previously Presented) A compound according to claim 80, wherein  $Q^1$  is independently  $C_{1-3}$ alkylene, and is optionally substituted.

93. (Previously Presented) A compound according to claim 80, wherein  $Q^1$  is independently :  $C_{1-7}$ alkylene- $X$ - $C_{1-7}$ alkylene,  $-X$ - $C_{1-7}$ alkylene, or  $C_{1-7}$ alkylene- $X$ -; wherein  $X$  is  $-O-$  or  $-S-$ ; and is optionally substituted.

94. (Previously Presented) A compound according to claim 80, wherein  $Q^1$  is independently  $:C_{1-3}alkylene-X-C_{1-3}alkylene$ ,  $-X-C_{1-3}alkylene$ , or  $C_{1-3}alkylene-X-$ ; wherein X is -O- or -S-; and is optionally substituted.

95. (Previously Presented) A compound according to claim 80, wherein substituents on  $Q^1$ , if present, are independently: halo, hydroxy, ether,  $C_{5-20}aryl$ , acyl, amino, amido, acylamido, or oxo.

96. (Previously Presented) A compound according to claim 80, wherein substituents on  $Q^1$ , if present, are independently: -F, -Cl, -Br, -I, -OH, -OMe, -OEt, -OPr, -Ph, -NH<sub>2</sub>, -CONH<sub>2</sub>, or =O.

97. (Previously Presented) A compound according to claim 80, wherein  $Q^1$ , if other than a covalent bond, is unsubstituted.

98. (Previously Presented) A compound according to claim 80, wherein  $Q^1$  is independently a covalent bond.

99. (Previously Presented) A compound according to claim 80, wherein:  $Q^1$  is independently a covalent bond;  $J^1$  is independently a covalent bond;  $J^2$  is independently -C(=O)-.

100. (Previously Presented) A compound according to claim 80, wherein:  $Q^1$  is independently a covalent bond;  $J^1$  is independently -C(=O)-;  $J^2$  is independently -C(=O)-.

101. (Previously Presented) A compound according to claim 80, wherein:  $Q^1$  is independently a covalent bond;  $J^1$  is independently a covalent bond;  $J^2$  is independently  $-S(=O)_2-$ .

102. (Previously Presented) A compound according to claim 80, wherein:  $Q^1$  is independently a covalent bond;  $J^1$  is independently  $-C(=O)-$ ;  $J^2$  is independently  $-S(=O)_2-$ .

103. (Previously Presented) A compound according to claim 80, wherein  $Q^2$  is independently:  $C_{4-8}$ alkylene; and is optionally substituted; and has a backbone length of at least 4 atoms.

104. (Previously Presented) A compound according to claim 80, wherein  $Q^2$  is independently a saturated aliphatic  $C_{4-8}$ alkylene group.

105. (Previously Presented) A compound according to claim 88, wherein  $Q^2$  is independently a saturated aliphatic  $C_{4-8}$ alkylene group.

106. (Previously Presented) A compound according to claim 89, wherein  $Q^2$  is independently a saturated aliphatic  $C_{4-8}$ alkylene group.

107. (Previously Presented) A compound according to claim 90, wherein  $Q^2$  is independently a saturated aliphatic  $C_{4-8}$ alkylene group.

108. (Previously Presented) A compound according to claim 91, wherein  $Q^2$  is independently a saturated aliphatic  $C_{4-8}$ alkylene group.

109. (Previously Presented) A compound according to claim 99, wherein  $Q^2$  is independently a saturated aliphatic  $C_{4-8}$ alkylene group.

110. (Previously Presented) A compound according to claim 100, wherein  $Q^2$  is independently a saturated aliphatic  $C_{4-8}$ alkylene group.

111. (Previously Presented) A compound according to claim 101, wherein  $Q^2$  is independently a saturated aliphatic  $C_{4-8}$ alkylene group.

112. (Previously Presented) A compound according to claim 102, wherein  $Q^2$  is independently a saturated aliphatic  $C_{4-8}$ alkylene group.

113. (Previously Presented) A compound according to claim 80, wherein  $Q^2$  is independently a saturated linear  $C_{4-8}$ alkylene group.

114. (Previously Presented) A compound according to claim 80, wherein  $Q^2$  is independently selected from:  $-(CH_2)_5-$ ;  $-(CH_2)_6-$ ;  $-(CH_2)_7-$ ;  $-(CH_2)_8-$ ;  $-CH(CH_3)CH_2CH_2CH_2CH_2-$ ;  $-CH_2CH_2CH_2CH_2CH(CH_3)-$ ;  $-CH_2CH_2CH_2CH=CH-$ ; and,  $-CH_2CH_2CH_2CH_2CH=CH-$ .

115. (Previously Presented) A compound according to claim 80, wherein  $Q^2$  is independently selected from:  $-(CH_2)_5-$ ,  $-(CH_2)_6-$ ,  $-(CH_2)_7-$ , and  $-(CH_2)_8-$ .

116. (Currently Amended) A compound according to claim 80, wherein  $Q^2$ , is independently:  $[[C_{5-20} \text{ arylene}; ]C_{5-20} \text{ arylene-}C_{1-7} \text{ alkylene}; C_{1-7} \text{ alkylene-}C_{5-20} \text{ arylene}; C_{1-7} \text{ alkylene-}C_{5-20} \text{ arylene-}C_{1-7} \text{ alkylene};$  or, and is optionally substituted; and has a backbone length of at least 4 atoms.

Claim 117. (Canceled)

Claim 118. (Canceled)

119. (Previously Presented) A compound according to claim 80, wherein  $Q^2$ , is independently:  $C_{5-6} \text{ arylene-}C_{1-7} \text{ alkylene}; C_{1-7} \text{ alkylene-}C_{5-6} \text{ arylene};$  or,  $C_{1-7} \text{ alkylene-}C_{5-6} \text{ arylene-}C_{1-7} \text{ alkylene};$  and is optionally substituted; and has a backbone length of at least 4 atoms.

120. (Previously Presented) A compound according to claim 80, wherein  $Q^2$ , is independently:  $\text{phenylene-}C_{1-7} \text{ alkylene}; C_{1-7} \text{ alkylene-phenylene};$  or,  $C_{1-7} \text{ alkylene-phenylene-}C_{1-7} \text{ alkylene};$  and is optionally substituted; and has a backbone length of at least 4 atoms.

121. (Previously Presented) A compound according to claim 80, wherein  $Q^2$ , is independently:  $\text{methylene-phenylene}; \text{ethylene-phenylene}; \text{phenylene-methylene};$   
 $\text{phenylene-ethylene}; \text{phenylene-ethenylene}; \text{methylene-phenylene-methylene};$   
 $\text{methylene-phenylene-ethylene}; \text{methylene-phenylene-ethenylene}; \text{ethylene-phenylene-}$   
 $\text{methylene}; \text{ethylene-phenylene-ethylene}; \text{ethylene-phenylene-ethenylene};$  and is optionally substituted; and has a backbone length of at least 4 atoms.



122. (Previously Presented) A compound according to claim 88, wherein  $Q^2$ , is independently: methylene-phenylene; ethylene-phenylene; phenylene-methylene; phenylene-ethylene; phenylene-ethenylene; methylene-phenylene-methylene; methylene-phenylene-ethylene; methylene-phenylene-ethenylene; ethylene-phenylene-methylene; ethylene-phenylene-ethylene; ethylene-phenylene-ethenylene; and is optionally substituted; and has a backbone length of at least 4 atoms.

123. (Previously Presented) A compound according to claim 89, wherein  $Q^2$ , is independently: methylene-phenylene; ethylene-phenylene; phenylene-methylene; phenylene-ethylene; phenylene-ethenylene; methylene-phenylene-methylene; methylene-phenylene-ethylene; methylene-phenylene-ethenylene; ethylene-phenylene-methylene; ethylene-phenylene-ethylene; ethylene-phenylene-ethenylene; and is optionally substituted; and has a backbone length of at least 4 atoms.

124. (Previously Presented) A compound according to claim 90, wherein  $Q^2$ , is independently: methylene-phenylene; ethylene-phenylene; phenylene-methylene; phenylene-ethylene; phenylene-ethenylene; methylene-phenylene-methylene; methylene-phenylene-ethylene; methylene-phenylene-ethenylene; ethylene-phenylene-methylene; ethylene-phenylene-ethylene; ethylene-phenylene-ethenylene; and is optionally substituted; and has a backbone length of at least 4 atoms.

125. (Previously Presented) A compound according to claim 91, wherein  $Q^2$ , is independently: methylene-phenylene; ethylene-phenylene; phenylene-methylene; phenylene-ethylene; phenylene-ethenylene; methylene-phenylene-methylene; methylene-phenylene-ethylene; methylene-phenylene-ethenylene; ethylene-phenylene-

methylene; ethylene-phenylene-ethylene; ethylene-phenylene-ethenylene; and is optionally substituted; and has a backbone length of at least 4 atoms.

126. (Previously Presented) A compound according to claim 99, wherein  $Q^2$ , is independently: methylene-phenylene; ethylene-phenylene; phenylene-methylene; phenylene-ethylene; phenylene-ethenylene; methylene-phenylene-methylene; methylene-phenylene-ethylene; methylene-phenylene-ethenylene; ethylene-phenylene-methylene; ethylene-phenylene-ethylene; ethylene-phenylene-ethenylene; and is optionally substituted; and has a backbone length of at least 4 atoms.

127. (Previously Presented) A compound according to claim 100, wherein  $Q^2$ , is independently: methylene-phenylene; ethylene-phenylene; phenylene-methylene; phenylene-ethylene; phenylene-ethenylene; methylene-phenylene-methylene; methylene-phenylene-ethylene; methylene-phenylene-ethenylene; ethylene-phenylene-methylene; ethylene-phenylene-ethylene; ethylene-phenylene-ethenylene; and is optionally substituted; and has a backbone length of at least 4 atoms.

128. (Previously Presented) A compound according to claim 101, wherein  $Q^2$ , is independently: methylene-phenylene; ethylene-phenylene; phenylene-methylene; phenylene-ethylene; phenylene-ethenylene; methylene-phenylene-methylene; methylene-phenylene-ethylene; methylene-phenylene-ethenylene; ethylene-phenylene-methylene; ethylene-phenylene-ethylene; ethylene-phenylene-ethenylene; and is optionally substituted; and has a backbone length of at least 4 atoms.


129. (Previously Presented) A compound according to claim 102, wherein  $Q^2$ , is independently: methylene-phenylene; ethylene-phenylene; phenylene-methylene; phenylene-ethylene; phenylene-ethenylene; methylene-phenylene-methylene; methylene-phenylene-ethylene; methylene-phenylene-ethenylene; ethylene-phenylene-methylene; ethylene-phenylene-ethylene; ethylene-phenylene-ethenylene; and is optionally substituted; and has a backbone length of at least 4 atoms.

130. (Previously Presented) A compound according to claim 120, wherein the phenylene linkage is meta or para.


131. (Previously Presented) A compound according to claim 120, wherein the phenylene linkage is meta.

132. (Previously Presented) A compound according to claim 120, wherein the phenylene linkage is para.

133. (Previously Presented) A compound according to claim 80, wherein  $Q^2$ , is independently:



134. (Previously Presented) A compound according to claim 80, wherein  $Q^2$ , is independently:



135. (Previously Presented) A compound according to claim 80, wherein Q<sup>2</sup> is substituted.

136. (Currently Amended) A compound according to claim 80, wherein substituents on Q<sup>2</sup>, if present, are independently selected from: (1) ester; (2) amido; (3) acyl; (4) halo; (5) hydroxy; (6) ether; (7) substituted or unsubstituted C<sub>1-7</sub>alkyl (8) substituted or unsubstituted C<sub>5-20</sub>aryl; (9) sulfonyl; (10) sulfonamido; (11) amino; (12) morpholino; (13) nitro; and (14) cyano.

137. (Currently Amended) A compound according to claim 80, wherein substituents on Q<sup>2</sup>, if present, are independently selected from:

(1) -C(=O)OMe, -C(=O)OEt, -C(=O)O(Pr), -C(=O)O(iPr), -C(=O)O(nBu), -C(=O)O(sBu), -C(=O)O(iBu), -C(=O)O(tBu), -C(=O)O(nPe); -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OH, -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OMe, -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OEt;

(2) -(C=O)NH<sub>2</sub>, -(C=O)NMe<sub>2</sub>, -(C=O)NEt<sub>2</sub>, -(C=O)N(iPr)<sub>2</sub>, -(C=O)N(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>;

(3) -(C=O)Me, -(C=O)Et, -(C=O)-cHex, -(C=O)Ph;

(4) -F, -Cl, -Br, -I;

(5) -OH;

(6) -OMe, -OEt, -O(iPr), -O(tBu), -OPh; -OCF<sub>3</sub>, -OCH<sub>2</sub>CF<sub>3</sub>; -OCH<sub>2</sub>CH<sub>2</sub>OH, -OCH<sub>2</sub>CH<sub>2</sub>OMe, -OCH<sub>2</sub>CH<sub>2</sub>OEt; -OCH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, -OCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>, -OCH<sub>2</sub>CH<sub>2</sub>N(iPr)<sub>2</sub>; -OPh, -OPh-Me, -OPh-OH, -OPh-OMe, -O-Ph-F, -OPh-Cl, -OPh-Br, -OPh-I;

(7) -Me, -Et, -nPr, -iPr, -nBu, -iBu, -sBu, -tBu, -nPe; -CF<sub>3</sub>, -CH<sub>2</sub>CF<sub>3</sub>; -CH<sub>2</sub>CH<sub>2</sub>OH, -CH<sub>2</sub>CH<sub>2</sub>OMe, -CH<sub>2</sub>CH<sub>2</sub>OEt; -CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>N(iPr)<sub>2</sub>; -CH<sub>2</sub>-Ph;

(8) -Ph, -Ph-Me, -Ph-OH, -Ph-OMe, -Ph-F, -Ph-Cl, -Ph-Br, -Ph-I;

(9) -SO<sub>2</sub>Me, -SO<sub>2</sub>Et, -SO<sub>2</sub>Ph;

(10) -SO<sub>2</sub>NH<sub>2</sub>, -SO<sub>2</sub>NMe<sub>2</sub>, -SO<sub>2</sub>NEt<sub>2</sub>;

(11) -NMe<sub>2</sub>, -NEt<sub>2</sub>;

(12) morpholino;

(13) -NO<sub>2</sub>; and

(14) -CN.

138. (Previously Presented) A compound according to claim 80, wherein Q<sup>2</sup> is unsubstituted.

139. (Previously Presented) A compound according to claim 80, wherein Q<sup>2</sup> has a backbone of at least 5 atoms.

140. (Previously Presented) A compound according to claim 80, wherein Q<sup>2</sup> has a backbone of at least 6 atoms.

141. (Previously Presented) A compound according to claim 80, wherein Cy is independently C<sub>3-20</sub>carbocyclyl; and is optionally substituted.

142. (Previously Presented) A compound according to claim 80, wherein Cy is independently C<sub>3-20</sub>carbocyclyl derived from one of the following: cyclopropane, cyclobutane, cyclopentane, cyclohexane, cyclopentene, cyclohexene, norbornane, adamantane, cyclopentanone, and cyclohexanone; and is optionally substituted.

143. (Previously Presented) A compound according to claim 80, wherein Cy is independently C<sub>3-20</sub>heterocyclyl; and is optionally substituted.

144. (Previously Presented) A compound according to claim 80, wherein Cy is independently C<sub>3-20</sub>heterocyclyl derived from one of the following: piperidine, azepine, tetrahydropyran, morpholine, azetidine, piperazine, imidazoline, piperazinedione, and oxazolinone; and is optionally substituted.

145. (Previously Presented) A compound according to claim 80, wherein Cy is independently C<sub>5-20</sub>aryl; and is optionally substituted.

146. (Previously Presented) A compound according to claim 80, wherein Cy is independently C<sub>5-20</sub>carboaryl or C<sub>5-20</sub>heteroaryl; and is optionally substituted.

147. (Previously Presented) A compound according to claim 105, wherein Cy is independently C<sub>5-20</sub>carboaryl or C<sub>5-20</sub>heteroaryl; and is optionally substituted.

148. (Previously Presented) A compound according to claim 106, wherein Cy is independently C<sub>5-20</sub>carboaryl or C<sub>5-20</sub>heteroaryl; and is optionally substituted.

149. (Previously Presented) A compound according to claim 107, wherein Cy is independently C<sub>5-20</sub>carboaryl or C<sub>5-20</sub>heteroaryl; and is optionally substituted.

150. (Previously Presented) A compound according to claim 108, wherein Cy is independently C<sub>5-20</sub>carboaryl or C<sub>5-20</sub>heteroaryl; and is optionally substituted.

151. (Previously Presented) A compound according to claim 109, wherein Cy is independently C<sub>5-20</sub>carboaryl or C<sub>5-20</sub>heteroaryl; and is optionally substituted.

152. (Previously Presented) A compound according to claim 110, wherein Cy is independently C<sub>5-20</sub>carboaryl or C<sub>5-20</sub>heteroaryl; and is optionally substituted.

153. (Previously Presented) A compound according to claim 111, wherein Cy is independently C<sub>5-20</sub>carboaryl or C<sub>5-20</sub>heteroaryl; and is optionally substituted.

154. (Previously Presented) A compound according to claim 112, wherein Cy is independently C<sub>5-20</sub>carboaryl or C<sub>5-20</sub>heteroaryl; and is optionally substituted.

155. (Previously Presented) A compound according to claim 122, wherein Cy is independently C<sub>5-20</sub>carboaryl or C<sub>5-20</sub>heteroaryl; and is optionally substituted.

156. (Previously Presented) A compound according to claim 123, wherein Cy is independently C<sub>5-20</sub>carboaryl or C<sub>5-20</sub>heteroaryl; and is optionally substituted.

157. (Previously Presented) A compound according to claim 124, wherein Cy is independently C<sub>5-20</sub>carboaryl or C<sub>5-20</sub>heteroaryl; and is optionally substituted.

158. (Previously Presented) A compound according to claim 125, wherein Cy is independently C<sub>5-20</sub>carboaryl or C<sub>5-20</sub>heteroaryl; and is optionally substituted.

159. (Previously Presented) A compound according to claim 126, wherein Cy is independently C<sub>5-20</sub>carboaryl or C<sub>5-20</sub>heteroaryl; and is optionally substituted.

160. (Previously Presented) A compound according to claim 127, wherein Cy is independently C<sub>5-20</sub>carboaryl or C<sub>5-20</sub>heteroaryl; and is optionally substituted.

161. (Previously Presented) A compound according to claim 128, wherein Cy is independently C<sub>5-20</sub>carboaryl or C<sub>5-20</sub>heteroaryl; and is optionally substituted.

162. (Previously Presented) A compound according to claim 129, wherein Cy is independently C<sub>5-20</sub>carboaryl or C<sub>5-20</sub>heteroaryl; and is optionally substituted.

163. (Previously Presented) A compound according to claim 80, wherein Cy is independently C<sub>5-20</sub>aryl derived from one of the following: benzene, pyridine, furan, indole, pyrrole, imidazole, pyrimidine, pyrazine, pyridazine, naphthalene, quinoline, indole, benzimidazole, benzothiofuran, fluorene, acridine, and carbazole; and is optionally substituted.

164. (Previously Presented) A compound according to claim 80, wherein Cy is independently an optionally substituted phenyl group.

165. (Previously Presented) A compound according to claim 80, wherein Cy is optionally substituted with one or more substituents selected from:



- (1) ester;
- (2) amido;
- (3) acyl;
- (4) halo;
- (5) hydroxy;
- (6) ether;
- (7) substituted or unsubstituted C<sub>1-7</sub>alkyl;
- (8) substituted or unsubstituted C<sub>5-20</sub>aryl;
- (9) sulfonyl;
- (10) sulfonamido;
- (11) amino;
- (12) morpholino;
- (13) nitro; and
- (14) cyano.

166. (Currently Amended) A compound according to claim 80, wherein Cy is optionally substituted with one or more substituents selected from:

(1) -C(=O)OMe, -C(=O)OEt, -C(=O)O(Pr), -C(=O)O(iPr), -C(=O)O(nBu),  
-C(=O)O(sBu), -C(=O)O(iBu), -C(=O)O(tBu), -C(=O)O(nPe); -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OH, -  
C(=O)OCH<sub>2</sub>CH<sub>2</sub>OMe, -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OEt;

(2) -(C=O)NH<sub>2</sub>, -(C=O)NMe<sub>2</sub>, -(C=O)NEt<sub>2</sub>, -(C=O)N(iPr)<sub>2</sub>, -(C=O)N(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>;

(3) -(C=O)Me, -(C=O)Et, -(C=O)-cHex, -(C=O)Ph;

(4) -F, -Cl, -Br, -I;

(5) -OH;

(6) -OMe, -OEt, -O(iPr), -O(tBu), -OPh; -OCF<sub>3</sub>, -OCH<sub>2</sub>CF<sub>3</sub>; -OCH<sub>2</sub>CH<sub>2</sub>OH, -  
OCH<sub>2</sub>CH<sub>2</sub>OMe, -OCH<sub>2</sub>CH<sub>2</sub>OEt; -OCH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, -OCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>, -OCH<sub>2</sub>CH<sub>2</sub>N(iPr)<sub>2</sub>; -  
OPh, -OPh-Me, -OPh-OH, -OPh-OMe, O-Ph-F, -OPh-Cl, -OPh-Br, -OPh-I;

(7) -Me, -Et, -nPr, -iPr, -nBu, -iBu, -sBu, -tBu, -nPe; -CF<sub>3</sub>, -CH<sub>2</sub>CF<sub>3</sub>; -CH<sub>2</sub>CH<sub>2</sub>OH,  
-CH<sub>2</sub>CH<sub>2</sub>OMe, -CH<sub>2</sub>CH<sub>2</sub>OEt; -CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>N(iPr)<sub>2</sub>; -CH<sub>2</sub>-Ph;

(8) -Ph, -Ph-Me, -Ph-OH, -Ph-OMe, -Ph-F, -Ph-Cl, -Ph-Br, -Ph-I;

(9) -SO<sub>2</sub>Me, -SO<sub>2</sub>Et, -SO<sub>2</sub>Ph;

(10) -SO<sub>2</sub>NH<sub>2</sub>, -SO<sub>2</sub>NMe<sub>2</sub>, -SO<sub>2</sub>NEt<sub>2</sub>;


(11) -NMe<sub>2</sub>, -NEt<sub>2</sub>;


(12) morpholino;







(13) -NO<sub>2</sub>; and







(14) -CN.








167. (Currently Amended) A compound according to claim 80, selected from the following compounds, and pharmaceutically acceptable salts, solvates, amides, esters, and ethers, chemically protected forms, and prodrugs thereof:




























,




,




,









,




,




,







,




,




,










,
















,



,







168. (Previously Presented) A composition comprising a compound according to claim 80 and a pharmaceutically acceptable carrier.

169. (Previously Presented) A method inhibiting HDAC in a cell comprising said cell with an effective amount of a compound according to claim 80.

170. (Previously Presented) A method for the treatment of a condition mediated by HDAC comprising administering to a subject suffering from a condition mediated by HDAC a therapeutically-effective amount of a compound according to claim 80.

171. (Previously Presented) A method for the treatment of a proliferative condition comprising administering to a subject suffering from a proliferative condition a therapeutically-effective amount of a compound according to claim 80.

172. (Previously Presented) A method for the treatment of cancer comprising administering to a subject suffering from cancer a therapeutically-effective amount of a compound according to claim 80.

173. (Previously Presented) A method for the treatment of psoriasis comprising administering to a subject suffering from psoriasis a therapeutically-effective amount of a compound according to claim 80.